Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System
Overall, these data represent a major shift in standard clinical practice toward molecularly guided treatments (targeted and immunotherapies) over conventional systemic chemotherapy. As guidelines continue to evolve and more precision therapeutics gain approval, we expect this gap to continue to widen.
Authors
- Alexa K. Dowdell (ORCID: https://orcid.org/0000-0003-4866-6293)
- Hoifung Poon (ORCID: https://orcid.org/0000-0002-9067-0918)
- Ryan Meng (ORCID: https://orcid.org/0000-0003-4168-8916)
- Walter J. Urba (ORCID: https://orcid.org/0000-0001-8414-3348)
- Bela Bapat
- Lauren Harold
- Cliff Wong (ORCID: https://orcid.org/0000-0001-7867-090X)
- Brock E. Schroeder (ORCID: https://orcid.org/0000-0002-0803-7209)
- Carlo Bifulco (ORCID: https://orcid.org/0000-0003-1922-6977)
- Rom S. Leidner (ORCID: https://orcid.org/0000-0003-0788-7938)
- Douglas Hanes (ORCID: https://orcid.org/0000-0001-7131-3096)
- Brian Piening (ORCID: https://orcid.org/0000-0002-2683-8157)
- Ann Vita
- Shu‐Ching Chang (ORCID: https://orcid.org/0000-0002-6534-0124)
- Roshanthi Weerasinghe (ORCID: https://orcid.org/0000-0002-6610-2865)
Institutions
- Microsoft (United States) (US)
- Illumina (United States) (US)
- Providence Portland Medical Center (US)
- Providence Health & Services (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1200/op.24.00226
- Citations
- 6
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.71
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Incyte